NewAmsterdam Pharma

05/13/2026

As we expand our clinical development efforts in Alzheimer’s disease, we’re looking for an experienced physician leader to help shape trial design, monitoring, data analysis, and interpretation across this important program.

Learn more about the Executive Medical Director, Alzheimer’s Disease, opportunity at NewAmsterdam Pharma and how you can help advance innovative science for patients.

https://newamsterdampharma.wd108.myworkdayjobs.com/New_Amsterdam_External_Career_Site

05/10/2026

Lipid-related markers play an important role in understanding cardiovascular risk.

In recognition of , we’re highlighting the importance of advancing lipid science to help improve how cardiovascular risk is identified and addressed.

Explore how LDL-C, Lp(a), and HDL-C fit into cardiovascular risk:
https://www.expectmoreforldl.com/ldl-c-goals-guidelines-and-treatment/

05/08/2026

May is , and it’s an important reminder that cardiovascular disease remains the leading cause of death in women. Women represent nearly half of all adults living with cardiovascular disease, and trends suggest the burden could grow without greater awareness, prevention, and support.

More attention to women’s heart health can help drive earlier conversations, better care, and improved outcomes.

Learn more: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001406

04/22/2026

On , we’re recognizing the colleagues who keep our teams running smoothly every day. Thank you for your organization, dedication, and steady support—your work makes a meaningful difference across the company and helps keep our focus where it belongs: on delivering for patients.

04/16/2026

Congratulations to our CEO, Dr. Michael Davidson who has been selected for the 2026 Foundation of the NLA Clinician/Educator Award.

From patient care to education, his work continues to elevate the field of clinical lipidology, and we’re proud to see it recognized on this stage.

See you at as we celebrate with National Lipid Association and Foundation of the National Lipid Association.

04/07/2026

On , we’re recognizing the importance of prevention, early detection, and access to care, particularly for cardiovascular disease, the leading cause of death worldwide.

We’re committed to advancing science that can help address unmet needs in cardiovascular disease and other lipid-related conditions and keeping patients at the heart of our work. Learn more about our focus: https://www.newamsterdampharma.com/

04/01/2026

We’re proud to see our Chief Scientific Officer, Prof. John Kastelein, honored by the Family Heart Foundation with the Pioneer Award.

Prof. Kastelein’s groundbreaking work has played a pivotal role in advancing how cardiovascular disease is understood and treated the understanding and treatment of cardiovascular disease around the world. This recognition reflects decades of scientific leadership and innovation that continue to drive progress for patients.

Congratulations, Prof. Kastelein, on this well-deserved honor. We’re grateful for your commitment to advancing scientific research and treatment options.

The Family Heart Foundation is proud to honor Dr. John Kastelein, University of Amsterdam, with the Pioneer Award at our 2026 Global Summit — Small Steps and Giant Leaps: Charting a Course for Cardiovascular Disease Prevention. Dr. Kastelein’s groundbreaking work in lipid science and cardiovascular prevention has helped shape how we understand and treat inherited cholesterol conditions. We are excited to announce him as the Pioneer Award winner and as a keynote speaker! Join us as we recognize his impact and hear his insights from decades of innovation. Register today for early bird pricing at https://FamilyHeart.org/Summit

03/31/2026

We are working to change the landscape of lipid-lowering treatment by advancing innovative therapies for cardiovascular disease (CVD) and other lipid-related conditions. As we continue to advance our Phase 3 clinical program, we will be hiring many roles and encourage you to follow us to learn more about our current openings and stay updated on future job postings: https://www.newamsterdampharma.com/careers/

03/26/2026

Diabetes and cardiovascular disease often intersect. Today, on , it’s important to understand lipid-related conditions and their role in long-term cardiovascular health. Learn more about lipid-related conditions and our focus: https://www.newamsterdampharma.com/lipid-related-conditions/

03/24/2026

Lipoprotein(a), or Lp(a), is an often under-recognized risk factor for cardiovascular disease. Since Lp(a) levels are largely genetically determined, lifestyle changes alone may not be enough to lower elevated risk, and many people are unaware of their levels without testing.

On , learn more about the role of Lp(a) in cardiovascular risk: https://www.expectmoreforldl.com/ldl-c-and-beyond/